Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
22.09
+0.78 (3.66%)
Dec 20, 2024, 4:00 PM EST - Market closed
Teva Pharmaceutical Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -959 | -559 | -2,446 | 417 | -3,990 | -999 | Upgrade
|
| Depreciation & Amortization | 1,056 | 1,153 | 1,308 | 1,330 | 1,557 | 1,722 | Upgrade
|
| Loss (Gain) From Sale of Assets | 7 | - | - | - | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 1,826 | 1,078 | 2,447 | 594 | 6,626 | 1,778 | Upgrade
|
| Loss (Gain) From Sale of Investments | -41 | -41 | 10 | 104 | -213 | -18 | Upgrade
|
| Stock-Based Compensation | 117 | 121 | 124 | 119 | 129 | 119 | Upgrade
|
| Other Operating Activities | -252 | -312 | -1,208 | -65 | -705 | -958 | Upgrade
|
| Change in Accounts Receivable | 12 | 12 | 334 | -574 | -293 | -394 | Upgrade
|
| Change in Inventory | -147 | -147 | -163 | 380 | 41 | 271 | Upgrade
|
| Change in Accounts Payable | 1,588 | 1,588 | 2,012 | 764 | -463 | 643 | Upgrade
|
| Change in Other Net Operating Assets | -1,351 | -1,525 | -828 | -2,271 | -1,473 | -1,416 | Upgrade
|
| Operating Cash Flow | 1,856 | 1,368 | 1,590 | 798 | 1,216 | 748 | Upgrade
|
| Operating Cash Flow Growth | 60.41% | -13.96% | 99.25% | -34.38% | 62.57% | -69.42% | Upgrade
|
| Capital Expenditures | -488 | -526 | -548 | -562 | -578 | -525 | Upgrade
|
| Cash Acquisitions | -15 | - | -7 | - | - | - | Upgrade
|
| Divestitures | 39 | 68 | 68 | 311 | 67 | 343 | Upgrade
|
| Investment in Securities | -18 | -46 | 3 | 125 | -43 | -6 | Upgrade
|
| Other Investing Activities | 1 | -5 | - | 1 | 12 | 56 | Upgrade
|
| Investing Cash Flow | 891 | 968 | 656 | 1,523 | 863 | 1,355 | Upgrade
|
| Short-Term Debt Issued | - | 700 | - | 700 | 550 | 500 | Upgrade
|
| Long-Term Debt Issued | - | 2,451 | - | 4,974 | - | 2,083 | Upgrade
|
| Total Debt Issued | - | 3,151 | - | 5,674 | 550 | 2,583 | Upgrade
|
| Short-Term Debt Repaid | - | -700 | - | -700 | -559 | -502 | Upgrade
|
| Long-Term Debt Repaid | - | -4,152 | -1,369 | -7,140 | -1,871 | -3,944 | Upgrade
|
| Total Debt Repaid | -1,456 | -4,852 | -1,369 | -7,840 | -2,430 | -4,446 | Upgrade
|
| Net Debt Issued (Repaid) | -1,456 | -1,701 | -1,369 | -2,166 | -1,880 | -1,863 | Upgrade
|
| Preferred Dividends Paid | - | - | - | - | - | -52 | Upgrade
|
| Dividends Paid | - | - | - | - | - | -52 | Upgrade
|
| Other Financing Activities | -237 | -212 | -118 | -6 | -5 | -11 | Upgrade
|
| Financing Cash Flow | -1,693 | -1,913 | -1,487 | -2,172 | -1,885 | -1,926 | Upgrade
|
| Foreign Exchange Rate Adjustments | 15 | -30 | -123 | -128 | 8 | 16 | Upgrade
|
| Net Cash Flow | 1,069 | 393 | 636 | 21 | 202 | 193 | Upgrade
|
| Free Cash Flow | 1,368 | 842 | 1,042 | 236 | 638 | 223 | Upgrade
|
| Free Cash Flow Growth | 125.00% | -19.19% | 341.53% | -63.01% | 186.10% | -87.58% | Upgrade
|
| Free Cash Flow Margin | 8.16% | 5.31% | 6.98% | 1.49% | 3.83% | 1.32% | Upgrade
|
| Free Cash Flow Per Share | 1.21 | 0.75 | 0.94 | 0.21 | 0.58 | 0.20 | Upgrade
|
| Cash Interest Paid | 1,078 | 1,078 | 948 | 913 | 846 | 840 | Upgrade
|
| Cash Income Tax Paid | 298 | 298 | 543 | 495 | 709 | 552 | Upgrade
|
| Levered Free Cash Flow | 3,867 | 3,294 | 2,900 | 2,307 | 1,764 | 2,128 | Upgrade
|
| Unlevered Free Cash Flow | 4,499 | 3,938 | 3,481 | 2,863 | 2,327 | 2,642 | Upgrade
|
| Change in Net Working Capital | -1,483 | -1,202 | -933 | -52 | 690 | 372 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.